These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 21518617

  • 1. [Safety and immunogenicity on the formulation of trivalent split influenza vaccine among healthy people aged over 18 years].
    Wang P, Zhang XW, Song YF, Yin HB, Liu LJ, Che L, Li H, Liu Y, Chen JT.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Feb; 32(2):120-4. PubMed ID: 21518617
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.
    Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
    [Abstract] [Full Text] [Related]

  • 3. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
    Shen Y, Hu Y, Meng F, Du W, Li W, Song Y, Ji X, Huo L, Fu Z, Yin W.
    Hum Vaccin Immunother; 2016 May 03; 12(5):1229-34. PubMed ID: 26934750
    [Abstract] [Full Text] [Related]

  • 4. [Safety and immunogenicity of seasonal inactivated influenza vaccine (split virion) and cross-reactive antibody responses to the H7N9 avian influenza virus].
    Guo W, Xu J, Wu J, Zhao S, He H, Shi W, Yu D, Li J, Gao H, Chen J.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Aug 03; 35(8):949-52. PubMed ID: 25376689
    [Abstract] [Full Text] [Related]

  • 5. [Safety and immunogenicity on three lots of influenza split vaccines among adults].
    Zhang ZL, Wang X, Zhu XJ, Zhang Y, Liu Y, Gao ZG, Liang M, Li L, Li JM, Liu RK, Dong XJ, Song GX, Zhang DC, Wang WQ, Han YG, Chen JT.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun 03; 30(6):583-7. PubMed ID: 19957624
    [Abstract] [Full Text] [Related]

  • 6. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 03; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.
    Microbiol Immunol; 2015 Oct 03; 59(10):597-604. PubMed ID: 26272602
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.
    Vaccine; 2011 Nov 21; 29(50):9391-7. PubMed ID: 21983154
    [Abstract] [Full Text] [Related]

  • 9. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.
    J Infect Dis; 2011 Jun 15; 203(12):1719-28. PubMed ID: 21606530
    [Abstract] [Full Text] [Related]

  • 10. [Safety and immunological effect of domestic split influenza virus vaccine].
    Zhang PR, Zhu XP, Zhou LJ, Liu YQ, Fan Y, Chen G, Chen Z, Liu Y, Sun HY, Wu JL.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jul 15; 43(7):615-8. PubMed ID: 19954075
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
    Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP.
    Hum Vaccin Immunother; 2014 Jul 15; 10(2):441-8. PubMed ID: 24240428
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.
    J Am Geriatr Soc; 2007 Oct 15; 55(10):1499-507. PubMed ID: 17908055
    [Abstract] [Full Text] [Related]

  • 13. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
    Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM.
    Vaccine; 2011 Nov 28; 29(51):9544-50. PubMed ID: 21986218
    [Abstract] [Full Text] [Related]

  • 14. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 28; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 15. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ.
    J Infect Dis; 2009 Sep 15; 200(6):849-57. PubMed ID: 19673652
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia.
    Souza AR, Braga JA, de Paiva TM, Loggetto SR, Azevedo RS, Weckx LY.
    Vaccine; 2010 Jan 22; 28(4):1117-20. PubMed ID: 20116631
    [Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
    Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, Boršo D, Frimmel S, Riebold D, Reisinger EC.
    Vaccine; 2011 Feb 01; 29(6):1228-34. PubMed ID: 21167116
    [Abstract] [Full Text] [Related]

  • 18. Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults.
    Song JY, Cheong HJ, Lee J, Wie SH, Park KH, Kee SY, Jeong HW, Kim YS, Noh JY, Choi WS, Park DW, Sohn JW, Kim WJ.
    Hum Vaccin Immunother; 2014 Feb 01; 10(10):2958-64. PubMed ID: 25483462
    [Abstract] [Full Text] [Related]

  • 19. [A survey of levels of antibodies against influenza viruses in the population of Wuxi City].
    You FX, Sun N, Ma GY, Wang MM, Sa D, Shi C, Wu JL, Lin X, Xiao Y, Qian YH, Jiang Y, Xie J, Ji YY, Guan HX.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct 01; 25(5):351-4. PubMed ID: 22338222
    [Abstract] [Full Text] [Related]

  • 20. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.
    Vaccine; 2012 Jul 13; 30(33):5030-7. PubMed ID: 22472791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.